Domain 4(도메인 4)란 무엇입니까?
Domain 4 도메인 4 - A 10,000-member DEDL was selected against sirtuin-1, 2, and 5 (SIRT1, 2, 5) and the BD1 and BD2 domains of bromodomain 4 (BRD4), respectively. [1] Genomic analysis and in vitro experimentation demonstrate that cell growth can be reduced by modulating MYCN overexpression via bromodomain 4 (BRD4) inhibition in both anaplastic and nonanaplastic Wilms tumor models. [2] The results showed that mannose receptor C-type lectin-like domain 4-8 of M. [3] miR-375-3p, bromodomain 4 (BRD4), phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) expression in myocardial tissues, and their reciprocals were identified. [4] The WHOQOL-BREF is composed of 24 items which are divided into four domains (domain 1: physical health; domain 2: psychological well-being; domain 3: social relationships; and domain 4: environment), plus two general items which were analyzed separately, totaling 26 items. [5] Initially named "Behaviour" Domain 4 was renamed "Behavioural Interactions" in the 2020 iteration of the model and was expanded to include three categories: interactions with the environment, interactions with other animals and interactions with humans. [6] The questionnaire was a nineteen-item self-administered questionnaire divided into four domains namely, social interaction (Domain 1), impairment in communication (Domain 2), repetitive behavior (Domain 3), characteristics of autism as a disorder and its comorbidities (Domain 4). [7] Bromodomain 4 (BRD4), an important epigenetic regulator, is involved in many bone-related pathologies via promoting osteoclast formation. [8] In Mycobacterium tuberculosis (Mtb), WhiB7 interacts with domain 4 of the primary sigma factor (σA4) in the RNA polymerase holoenzyme and activates genes involved in multiple drug resistance and redox homeostasis. [9] We previously reported that BEL1-LIKE HOMEODOMAIN 4 ( SlBL4 ) is involved in chloroplast development and cell wall metabolism in tomato fruit. [10] The structure of a designed ankyrin-repeat protein that selectively binds to domain 4 of HER3, an important driver of malignant growth in many tumors, has been determined. [11] For survey domain 1 (level of understanding of power relationships), domain 2 (level of understanding of the interrelationship between culture and self-perceived health), domain 3 (level of understanding of the importance of culture in clinical practice and access to health care), and domain 4 (level of confidence with providing culturally safe care) a statistically significant ( p < 0. [12] Eight reviews had a high risk of bias in study eligibility criteria (domain 1), five for study identification and selection (domain 2), seven for data collection and appraisal (domain 3) and seven for synthesis and findings (domain 4). [13] The Delphi panel recommended an ideal infection control guideline should encompass six domains: general characteristics (domain-1), engineering recommendations (domain-2), personal protection equipment (PPE) use (domain-3), and administrative aspects (domain 4-6) of infection control. [14] Of the five Domains, Domain 4 (End-user Characteristics) and Domain 3 (Inner Settings) scored highest in Importance (8. [15] Results The median quality of life score was 81 with interquartile range of 75–81 in Domain 1(Physical health), 69 with interquartile range of 56–75 in Domain 2(Psychological domain), 75 with interquartile range of 56–75 in Domain 3(Social relationships) and 69 with interquartile range of 63–75 in Domain 4 (Environment). [16] Domain 4 identified a small and variable CAMHS workforce across all levels of care. [17] Domain 4, environment, displayed significant differences between all groups, with the aligner group scoring highest (32. [18] 4%, domain 4). [19] This led to the identification of a new potent and selective CBP/EP300 bromodomain inhibitor, UMB298 (compound 23, CBP IC50 72 nM and bromodomain 4, BRD4 IC50 5193 nM). [20] Bromodomain 4 (BRD4) proteins play an important role in histone post-translational modifications and facilitate several important physiological and pathological processes, including cancers. [21] Enhanced expression and nuclear retention of SE components like BET bromodomain 4 (BRD4) and p300 were found in infected BMDMs. [22] Recent studies using cholesterol-binding bacterial toxins such as domain 4 of Anthrolysin O (ALOD4) and fungal toxins such as Ostreolysin A (OlyA) have revealed new insights into the organization of PM cholesterol. [23] 1%, domain 4 clarity of presentation 80. [24] XMD8-92 is a small molecule inhibitor that blocks inflammatory activity downstream of ERK5 (extracellular signal-related kinase 5) and BRD4 (bromodomain 4). [25] 35 and domain 4 (environment) ‘r’ value is 0. [26] The MYC oncogene regulated lnc-HLX-2-7, and the small-molecule bromodomain and extraterminal domain family‒bromodomain 4 inhibitor Jun Qi 1 (JQ1) reduced lnc-HLX-2-7 expression. [27] Among the 24 CPGs subjected to AGREE II assessment, median domain scores were 74% for "Domain 1: Scope and Purpose," 43% for "Domain 2: Stakeholder Involvement," 46% for "Domain 3: Rigor of Development," 69% for "Domain 4: Clarity of Presentation," 24% for "Domain 5: Applicability" and 27% for "Domain 6: Editorial Independence. [28] Polo-like kinase 1 (PLK1) and bromodomain 4 (BRD4) are both attractive therapeutic targets in acute myeloid leukemia (AML). [29] The ten ND found predominantly related to the domains “activity / rest” (domain 4) and “safety / protection” (domain 11), with four NDs in each. [30] behavioral salience and then domain 4, i. [31] The reported binding conformation of CurE is deeply buried in the subdomain 4 of actin and is closely situated to the ATP-binding site. [32] The floor effects in all domains were below 15%, the ceiling effects were over 15% in overall score and in Domain 4. [33] 006); Domain 4 in naming numbers (p = 0. [34] 016), domain 4 (perceptual problems; p=0. [35] ResultsUnivariate analysis showed that demographic characteristics, including occupation, educational level, monthly income and speaking background; clinical characteristics, including lesions in the frontal and temporal lobes, and concurrent dysphagia; and PD-associated evaluations, including the activity of daily living (ADL) score, non-motor symptoms scale (NMSS) domain 4 score (perceptual problem), and NMSS domain 5 score (attention/memory) were all significantly different between the MSD and non-MSD group (all P < 0. [36] In class II transcription activation, the transcription factor normally binds to the promoter near the −35 position and contacts the domain 4 of σ factors (σ4) to activate transcription. [37] The appraisers gave passing marks to only two of the six domains in the AGREE II instrument: Domain 1 – Scope and Purpose (73%), and Domain 4 – Clarity of Presentation (74%). [38] Regression analysis revealed that Domain 3 (Rigour of Development), Domain 4 (Clarity of Presentation), Domain 5 (Applicability), and Domain 6 (Editorial Independence) had influence on the overall assessment. [39] Recent studies using two cholesterol-binding bacterial toxin proteins, perfringolysin O (PFO) and domain 4 of anthrolysin O (ALOD4), have shown that cholesterol in the plasma membranes (PMs) of animal cells resides in three distinct pools. [40] MTM performance component measures used to evaluate and rank pharmacy MTM performance mirrored measures under Domain 4 (Drug Safety and Accuracy of Drug Pricing) of the 2017 CMS Medicare Part D Plan’ Star Rating measures. [41] Several of the F‐spondin‐like domains have insertions in the canonical TSP fold, most notably the coiled coil region in domain 4, which may be utilized in protein‐protein binding interactions, suggesting that this protein functions as a heparan sulfate binding site. [42] The aim of the research is to check whether the selected protein fragment of the protective antigen (domain 4) encoded by an appropriate nucleotide sequence of gene pag of B. [43] The quality of these guidelines was relatively high in domain 1 (scope and purpose) and domain 4 (clarity of presentation), and medium in domain 2 (stakeholder involvement). [44]Sirtuin-1, 2, 5(SIRT1, 2, 5)와 bromodomain 4(BRD4)의 BD1 및 BD2 도메인에 대해 10,000명의 구성원 DEDL이 선택되었습니다. [1] 게놈 분석 및 시험관 내 실험은 역형성 및 비역형성 Wilms 종양 모델 모두에서 브로모도메인 4(BRD4) 억제를 통해 MYCN 과발현을 조절함으로써 세포 성장을 감소시킬 수 있음을 보여줍니다. [2] 그 결과 M. [3] 심근 조직에서 miR-375-3p, bromodomain 4(BRD4), phosphoinositide 3-kinase(PI3K) 및 protein kinase B(AKT) 발현과 이들의 역수를 확인했습니다. [4] WHOQOL-BREF는 4개 영역(영역 1: 신체적 건강, 영역 2: 심리적 웰빙, 영역 3: 사회적 관계, 영역 4: 환경)으로 구분된 24개 항목과 분석된 2개의 일반 항목으로 구성됩니다. 별도로 총 26개 항목입니다. [5] 처음에 "행동"이라는 이름의 도메인 4는 모델의 2020 반복에서 "행동 상호 작용"으로 이름이 바뀌었고 환경과의 상호 작용, 다른 동물과의 상호 작용 및 인간과의 상호 작용이라는 세 가지 범주를 포함하도록 확장되었습니다. [6] 설문지는 사회적 상호작용(도메인 1), 의사소통 장애(도메인 2), 반복적 행동(도메인 3), 장애로서의 자폐의 특징 및 동반질환(도메인)의 4개 영역으로 나누어진 19개 항목의 자가 관리형 설문지였습니다. 4). [7] 중요한 후성유전 조절자인 브로모도메인 4(BRD4)는 파골세포 형성 촉진을 통해 많은 뼈 관련 병리에 관여합니다. [8] Mycobacterium tuberculosis(Mtb)에서 WhiB7은 RNA 중합효소 홀로효소의 1차 시그마 인자(σA4)의 도메인 4와 상호작용하고 다중 약물 내성 및 산화환원 항상성에 관련된 유전자를 활성화합니다. [9] 우리는 이전에 BEL1-LIKE HOMEODOMAIN 4( SlBL4 )가 토마토 과일의 엽록체 발달 및 세포벽 대사에 관여한다고 보고했습니다. [10] 많은 종양에서 악성 성장의 중요한 동인인 HER3의 도메인 4에 선택적으로 결합하는 설계된 안키린 반복 단백질의 구조가 결정되었습니다. [11] 조사의 경우 영역 1(권력 관계에 대한 이해 수준), 영역 2(문화와 자기 인식 건강 간의 상호 관계에 대한 이해 수준), 영역 3(임상 실습 및 의료 접근에서 문화의 중요성에 대한 이해 수준) ), 그리고 영역 4(문화적으로 안전한 치료를 제공하는 신뢰도)는 통계적으로 유의미합니다( p < 0. [12] 8건의 리뷰는 연구 적격성 기준(도메인 1), 5건은 연구 식별 및 선택(도메인 2), 7건은 데이터 수집 및 평가(도메인 3), 7건은 종합 및 결과(도메인 4)에 대한 높은 편향 위험이 있었습니다. [13] Delphi 패널은 이상적인 감염 관리 지침이 6가지 영역을 포함해야 한다고 권고했습니다. 일반적인 특성(도메인-1), 엔지니어링 권장 사항(도메인-2), 개인 보호 장비(PPE) 사용(도메인-3), 관리적 측면(도메인 4- 6) 감염 관리. [14] 5개 도메인 중 도메인 4(최종 사용자 특성)와 도메인 3(내부 설정)이 중요도에서 가장 높은 점수를 받았습니다(8. [15] 결과 삶의 질 중앙값 점수는 영역 1(신체 건강)에서 사분위수 범위 75-81, 영역 2(심리적 영역)에서 사분위 범위 69, 영역 56-75 사분위수 범위 75였습니다. 3(사회적 관계) 및 69(영역 4(환경)에서 사분위수 범위 63–75). [16] 도메인 4는 모든 수준의 치료에 걸쳐 작고 가변적인 CAMHS 인력을 식별했습니다. [17] 도메인 4, 환경은 모든 그룹 간에 상당한 차이를 보였고, 얼라이너 그룹이 가장 높은 점수를 받았습니다(32. [18] 4%, 도메인 4). [19] 이를 통해 새로운 강력하고 선택적인 CBP/EP300 브로모도메인 억제제 UMB298(화합물 23, CBP IC50 72 nM 및 브로모도메인 4, BRD4 IC50 5193 nM)이 확인되었습니다. [20] 브로모도메인 4(BRD4) 단백질은 히스톤 번역 후 변형에서 중요한 역할을 하며 암을 비롯한 여러 중요한 생리학적 및 병리학적 과정을 촉진합니다. [21] BET 브로모도메인 4(BRD4) 및 p300과 같은 SE 구성요소의 향상된 발현 및 핵 보유가 감염된 BMDM에서 발견되었습니다. [22] 안트로리신 O(ALOD4)의 도메인 4와 같은 콜레스테롤 결합 박테리아 독소와 오스트레오리신 A(OlyA)와 같은 곰팡이 독소를 사용한 최근 연구는 PM 콜레스테롤의 조직에 대한 새로운 통찰력을 보여주었습니다. [23] 1%, 도메인 4 프레젠테이션의 선명도 80. [24] XMD8-92는 ERK5(세포외 신호 관련 키나제 5) 및 BRD4(브로모도메인 4)의 다운스트림 염증 활성을 차단하는 소분자 억제제입니다. [25] 35 및 도메인 4(환경) 'r' 값은 0입니다. [26] MYC 종양 유전자는 lnc-HLX-2-7을 조절하고, 소분자 브로모도메인 및 말단 외 도메인 패밀리-브로모도메인 4 억제제 Jun Qi 1(JQ1)은 lnc-HLX-2-7 발현을 감소시켰습니다. [27] nan [28] nan [29] nan [30] nan [31] nan [32] nan [33] nan [34] nan [35] nan [36] nan [37] nan [38] nan [39] nan [40] nan [41] nan [42] nan [43] nan [44]
repeat domain phosphoinositide
Abbreviations: ATG/Atg: autophagy related; BPAN: ß-propeller protein associated neurodegeneration; CNS: central nervous system; DEE: developmental and epileptic encephalopathy; EEG: electroencephalograph; ENO2/neuron-specific enolase, enolase 2; EOEE: early-onset epileptic encephalopathy; ER: endoplasmic reticulum; ID: intellectual disability; IDR: intrinsically disordered region; MRI: magnetic resonance imaging; NBIA: neurodegeneration with brain iron accumulation; NCOA4: nuclear receptor coactivator 4; PtdIns3P: phosphatidylinositol-3-phosphate; RLS: Rett-like syndrome; WDR45: WD repeat domain 45; WIPI: WD repeat domain, phosphoinositide interacting. [1] Abbreviations: AO: antimycin A and oligomycin; Ash: assembly helper; ATG: autophagy-related; BCAS3: BCAS3 microtubule associated cell migration factor; C16orf70: chromosome 16 open reading frame 70; DAPI: 4‘,6-diamidino-2-phenylindole; DKO: double knockout; DMSO: dimethyl sulfoxide; ER: endoplasmic reticulum; fluoppi: fluorescent-based technology detecting protein-protein interactions; FIS1: fission, mitochondrial 1; FKBP: FKBP prolyl isomerase family member 1C; FRB: FKBP-rapamycin binding; hAG: humanized azami-green; IP: immunoprecipitation; IRES: internal ribosome entry site; KO: knockout; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MFN2: mitofusin 2; MS: mass spectrometry; MT-CO2: mitochondrially encoded cytochrome c oxidase II; mtDNA: mitochondrial DNA; OPTN: optineurin; PFA: paraformaldehyde; PE: phosphatidylethanolamine; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; PtdIns(3,5)P2: phosphatidylinositol-3,5-bisphosphate; PINK1: PTEN induced kinase 1; PRKN/Parkin: parkin RBR E3 ubiquitin protein ligase; PROPPIN: β-propellers that bind polyphosphoinositides; RB1CC1/FIP200: RB1 inducible coiled-coil 1; TOMM20: translocase of outer mitochondrial membrane 20; ULK1: unc-51 like autophagy activating kinase 1; WDR45B/WIPI3: WD repeat domain 45B; WDR45/WIPI4: WD repeat domain 45; WIPI: WD repeat domain, phosphoinositide interacting; WT: wild type; ZFYVE1/DFCP1: zinc finger FYVE-type containing 1. [2] Mammalian cells contain four Atg18 homologs, belonging to two subclasses, WIPI1 (WD repeat domain, phosphoinositide interacting 1), WIPI2 and WDR45B/WIPI3 (WD repeat domain 45B), WDR45/WIPI4. [3]약어: ATG/Atg: 자가포식 관련; BPAN: ß-프로펠러 단백질 관련 신경변성; CNS: 중추신경계; DEE: 발달 및 간질성 뇌병증; EEG: 뇌파계; ENO2/뉴런-특이적 에놀라제, 에놀라제 2; EOEE: 조기 발병 간질 뇌병증; ER: 소포체; 아이디: 지적 장애; IDR: 본질적으로 무질서한 영역; MRI: 자기 공명 영상; NBIA: 뇌의 철분 축적을 동반한 신경변성; NCOA4: 핵 수용체 공동활성화제 4; PtdIns3P: 포스파티딜이노시톨-3-포스페이트; RLS: 레트형 증후군; WDR45: WD 반복 도메인 45; WIPI: WD 반복 도메인, 포스포이노시티드 상호작용. [1] 약어: AO: 안티마이신 A 및 올리고마이신; 애쉬: 어셈블리 도우미; ATG: 자가포식 관련; BCAS3: BCAS3 미세소관 관련 세포 이동 인자; C16orf70: 16번 염색체 오픈 리딩 프레임 70; DAPI: 4',6-디아미디노-2-페닐인돌; DKO: 더블 녹아웃; DMSO: 디메틸 설폭사이드; ER: 소포체; Fluoppi: 단백질-단백질 상호작용을 검출하는 형광 기반 기술; FIS1: 분열, 미토콘드리아 1; FKBP: FKBP 프롤릴 이성화효소 패밀리 구성원 1C; FRB: FKBP-라파마이신 결합; hAG: 인간화 아자미-그린; IP: 면역침전; IRES: 내부 리보솜 진입 부위; KO: 녹아웃; MAP1LC3B/LC3B: 미세소관 관련 단백질 1 경쇄 3 베타; MFN2: 미토푸신 2; MS: 질량 분석법; MT-CO2: 미토콘드리아로 암호화된 시토크롬 c 산화효소 II; mtDNA: 미토콘드리아 DNA; OPTN: 옵티뉴린; PFA: 파라포름알데히드; PE: 포스파티딜에탄올아민; PtdIns3K: 포스파티딜이노시톨 3-키나제; PtdIns3P: 포스파티딜이노시톨-3-포스페이트; PtdIns(3,5)P2: 포스파티딜이노시톨-3,5-비스포스페이트; PINK1: PTEN 유도 키나제 1; PRKN/Parkin: 파킨 RBR E3 유비퀴틴 단백질 리가제; PROPPIN: 폴리포스포이노시티드에 결합하는 β-프로펠러; RB1CC1/FIP200: RB1 유도 코일 코일 1; TOMM20: 외부 미토콘드리아 막의 트랜스로카제 20; ULK1: autophagy 활성화 키나제 1과 같은 unc-51; WDR45B/WIPI3: WD 반복 도메인 45B; WDR45/WIPI4: WD 반복 도메인 45; WIPI: WD 반복 도메인, 포스포이노시티드 상호작용; WT: 야생형; ZFYVE1/DFCP1: 1을 포함하는 징크 핑거 FYVE 유형. [2] nan [3]
purified full length
subtilis CdaACD domain and purified full-length GlmM or the GlmMF369 variant lacking the C-terminal flexible domain 4, that the cyclase and phosphoglucomutase form a stable complex in vitro and that GlmM is a potent cyclase inhibitor. [1] subtilis CdaACD catalytic domain and purified full-length GlmM or the GlmMF369 variant lacking the C-terminal flexible domain 4, we show that the cyclase and phosphoglucomutase form a stable complex in vitro and that GlmM is a potent cyclase inhibitor. [2] subtilis CdaACD domain and purified full-length GlmM or the GlmMF369 variant lacking the C-terminal flexible domain 4, that the cyclase and phosphoglucomutase form a stable complex in vitro and that GlmM is a potent cyclase inhibitor. [3]subtilis CdaACD 도메인 및 정제된 전장 GlmM 또는 C-말단 가요성 도메인 4가 없는 GlmMF369 변이체, cyclase 및 phosphoglucomutase가 시험관 내에서 안정한 복합체를 형성하고 GlmM이 강력한 cyclase 억제제임을 확인합니다. [1] subtilis CdaACD 촉매 도메인 및 정제된 전장 GlmM 또는 C-말단 유연한 도메인 4가 결여된 GlmMF369 변이체에서 우리는 cyclase와 phosphoglucomutase가 시험관 내에서 안정적인 복합체를 형성하고 GlmM이 강력한 cyclase 억제제임을 보여줍니다. [2] subtilis CdaACD 도메인 및 정제된 전장 GlmM 또는 C-말단 가요성 도메인 4가 없는 GlmMF369 변이체, cyclase 및 phosphoglucomutase가 시험관 내에서 안정한 복합체를 형성하고 GlmM이 강력한 cyclase 억제제임을 확인합니다. [3]
nucleotide oligomerization domain
We aimed to scrutinize the effects of leptin on nucleotide oligomerization domain-like receptors containing pyrin domain 3 (NLRP3), nucleotide oligomerization domain-like receptors with caspase activation and recruitment domain 4 (NLRC4), and nucleotide oligomerization domain-like receptors with caspase activation and recruitment domain 3 (NLRC3), as an essential part of the immune system, in ventilator-induced lung injury (VILI) of rats. [1]우리는 피린 도메인 3(NLRP3), 카스파제 활성화 및 모집 도메인 4(NLRC4)가 있는 뉴클레오티드 올리고머화 도메인 유사 수용체, 카스파제 활성화가 있는 뉴클레오티드 올리고머화 도메인 유사 수용체를 포함하는 뉴클레오티드 올리고머화 도메인 유사 수용체에 대한 렙틴의 효과를 조사하는 것을 목표로 했습니다. 및 쥐의 인공호흡기 유발 폐 손상(VILI)에서 면역계의 필수 부분인 모집 도메인 3(NLRC3). [1]
Repeat Domain 4
Furthermore, we found that GLCCI1 bound with WD repeat domain 45B (WDR45B) and inhibited its expression. [1] Recent publications have presented research showing that WD repeat domain 4 (WDR4) plays a significant role in various kinds of malignant tumours. [2] Abbreviations: ATG/Atg: autophagy related; BPAN: ß-propeller protein associated neurodegeneration; CNS: central nervous system; DEE: developmental and epileptic encephalopathy; EEG: electroencephalograph; ENO2/neuron-specific enolase, enolase 2; EOEE: early-onset epileptic encephalopathy; ER: endoplasmic reticulum; ID: intellectual disability; IDR: intrinsically disordered region; MRI: magnetic resonance imaging; NBIA: neurodegeneration with brain iron accumulation; NCOA4: nuclear receptor coactivator 4; PtdIns3P: phosphatidylinositol-3-phosphate; RLS: Rett-like syndrome; WDR45: WD repeat domain 45; WIPI: WD repeat domain, phosphoinositide interacting. [3] Abbreviations: AO: antimycin A and oligomycin; Ash: assembly helper; ATG: autophagy-related; BCAS3: BCAS3 microtubule associated cell migration factor; C16orf70: chromosome 16 open reading frame 70; DAPI: 4‘,6-diamidino-2-phenylindole; DKO: double knockout; DMSO: dimethyl sulfoxide; ER: endoplasmic reticulum; fluoppi: fluorescent-based technology detecting protein-protein interactions; FIS1: fission, mitochondrial 1; FKBP: FKBP prolyl isomerase family member 1C; FRB: FKBP-rapamycin binding; hAG: humanized azami-green; IP: immunoprecipitation; IRES: internal ribosome entry site; KO: knockout; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MFN2: mitofusin 2; MS: mass spectrometry; MT-CO2: mitochondrially encoded cytochrome c oxidase II; mtDNA: mitochondrial DNA; OPTN: optineurin; PFA: paraformaldehyde; PE: phosphatidylethanolamine; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; PtdIns(3,5)P2: phosphatidylinositol-3,5-bisphosphate; PINK1: PTEN induced kinase 1; PRKN/Parkin: parkin RBR E3 ubiquitin protein ligase; PROPPIN: β-propellers that bind polyphosphoinositides; RB1CC1/FIP200: RB1 inducible coiled-coil 1; TOMM20: translocase of outer mitochondrial membrane 20; ULK1: unc-51 like autophagy activating kinase 1; WDR45B/WIPI3: WD repeat domain 45B; WDR45/WIPI4: WD repeat domain 45; WIPI: WD repeat domain, phosphoinositide interacting; WT: wild type; ZFYVE1/DFCP1: zinc finger FYVE-type containing 1. [4] The effector-target relationship between miR-133a-3p and ankyrin repeat domain 44 (ANKRD44) was confirmed by bioinformatics and a dual luciferase assay. [5] Thus, the goal of the present study was to investigate the function and mechanism of the m7G methyltransferase WD repeat domain 4 (WDR4) in HCC as well as its clinical relevance and potential value. [6] Sde1A encodes a protein with a RAWUL domain, which is also present in Polycomb Group Repressive Complex 1 (PRC1) RING finger proteins and WD Repeat Domain 48 proteins. [7] Abbreviation: ALP: autophagy-lysosome pathway; ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ASO: antisense oligonucleotide; C9orf72: C9orf72-SMCR8 complex subunit; DENN: differentially expressed in normal and neoplastic cells; DPR: dipeptide repeat protein; EIF2A/eIF2α: eukaryotic translation initiation factor 2A; ER: endoplasmic reticulum; FTD: frontotemporal dementia; GAP: GTPase-activating protein; GEF: guanine nucleotide exchange factor; HRE: hexanucleotide repeat expansion; iPSC: induced pluripotent stem cell; ISR: integrated stress response; M6PR: mannose-6-phosphate receptor, cation dependent; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MN: motor neuron; MTORC1: mechanistic target of rapamycin kinase complex 1; ND: neurodegenerative disorder; RAN: repeat-associated non-ATG; RB1CC1/FIP200: RB1 inducible coiled-coil 1; SLC66A1/PQLC2: solute carrier family 66 member 1; SMCR8: SMCR8-C9orf72 complex subunit; SQSTM1/p62: sequestosome 1; STX17: syntaxin 17; TARDBP/TDP-43: TAR DNA binding protein; TBK1: TANK binding kinase 1; TFEB: transcription factor EB; ULK1: unc-51 like autophagy activating kinase 1; UPS: ubiquitin-proteasome system; WDR41: WD repeat domain 41. [8] This interaction is counteracted by the microtubule-associated WD40-repeat domain 47 protein (WDR47). [9] To the Editor Beta-propeller protein–associated neurodegeneration (BPAN) is a subtype of neurodegeneration with brain iron accumulation (NBIA), caused by mutations in the WD repeat domain 45 (WDR45) gene on chromosomeX that has a key role in the autophagy pathway [1]. [10] WD repeat domain 45 (WDR45) gene has been increasingly found in patients with developmental delay (DD) and epilepsy. [11] Mammalian cells contain four Atg18 homologs, belonging to two subclasses, WIPI1 (WD repeat domain, phosphoinositide interacting 1), WIPI2 and WDR45B/WIPI3 (WD repeat domain 45B), WDR45/WIPI4. [12]또한, 우리는 GLCCI1이 WD 반복 도메인 45B(WDR45B)와 결합하여 그 발현을 억제한다는 것을 발견했습니다. [1] 최근 간행물은 WD 반복 도메인 4(WDR4)가 다양한 종류의 악성 종양에서 중요한 역할을 한다는 것을 보여주는 연구를 발표했습니다. [2] 약어: ATG/Atg: 자가포식 관련; BPAN: ß-프로펠러 단백질 관련 신경변성; CNS: 중추신경계; DEE: 발달 및 간질성 뇌병증; EEG: 뇌파계; ENO2/뉴런-특이적 에놀라제, 에놀라제 2; EOEE: 조기 발병 간질 뇌병증; ER: 소포체; 아이디: 지적 장애; IDR: 본질적으로 무질서한 영역; MRI: 자기 공명 영상; NBIA: 뇌의 철분 축적을 동반한 신경변성; NCOA4: 핵 수용체 공동활성화제 4; PtdIns3P: 포스파티딜이노시톨-3-포스페이트; RLS: 레트형 증후군; WDR45: WD 반복 도메인 45; WIPI: WD 반복 도메인, 포스포이노시티드 상호작용. [3] 약어: AO: 안티마이신 A 및 올리고마이신; 애쉬: 어셈블리 도우미; ATG: 자가포식 관련; BCAS3: BCAS3 미세소관 관련 세포 이동 인자; C16orf70: 16번 염색체 오픈 리딩 프레임 70; DAPI: 4',6-디아미디노-2-페닐인돌; DKO: 더블 녹아웃; DMSO: 디메틸 설폭사이드; ER: 소포체; Fluoppi: 단백질-단백질 상호작용을 검출하는 형광 기반 기술; FIS1: 분열, 미토콘드리아 1; FKBP: FKBP 프롤릴 이성화효소 패밀리 구성원 1C; FRB: FKBP-라파마이신 결합; hAG: 인간화 아자미-그린; IP: 면역침전; IRES: 내부 리보솜 진입 부위; KO: 녹아웃; MAP1LC3B/LC3B: 미세소관 관련 단백질 1 경쇄 3 베타; MFN2: 미토푸신 2; MS: 질량 분석법; MT-CO2: 미토콘드리아로 암호화된 시토크롬 c 산화효소 II; mtDNA: 미토콘드리아 DNA; OPTN: 옵티뉴린; PFA: 파라포름알데히드; PE: 포스파티딜에탄올아민; PtdIns3K: 포스파티딜이노시톨 3-키나제; PtdIns3P: 포스파티딜이노시톨-3-포스페이트; PtdIns(3,5)P2: 포스파티딜이노시톨-3,5-비스포스페이트; PINK1: PTEN 유도 키나제 1; PRKN/Parkin: 파킨 RBR E3 유비퀴틴 단백질 리가제; PROPPIN: 폴리포스포이노시티드에 결합하는 β-프로펠러; RB1CC1/FIP200: RB1 유도 코일 코일 1; TOMM20: 외부 미토콘드리아 막의 트랜스로카제 20; ULK1: autophagy 활성화 키나제 1과 같은 unc-51; WDR45B/WIPI3: WD 반복 도메인 45B; WDR45/WIPI4: WD 반복 도메인 45; WIPI: WD 반복 도메인, 포스포이노시티드 상호작용; WT: 야생형; ZFYVE1/DFCP1: 1을 포함하는 징크 핑거 FYVE 유형. [4] nan [5] nan [6] nan [7] nan [8] nan [9] nan [10] nan [11] nan [12]
Binding Domain 4
Using purified proteins, we show that Ply, through its cholesterol-binding domain 4, interacts with the neuronal plasma membrane, thereby increasing the exposure on the outer surface of β-actin filaments, leading to more β-actin binding sites available for RrgA binding, and thus enhanced pneumococcal interactions with neurons. [1] G:T mismatches, the major mispairs generated during DNA metabolism, are repaired in part by mismatch-specific DNA glycosylases such as methyl-CpG-binding domain 4 (MBD4) and thymine DNA glycosylase (TDG). [2] The ability of piperine to interact with the key amino acids in the receptor binding domain 4L3N as indicated by its docking configuration, rationalized its observed activity. [3] Methods We explored the prognostic correlation between 7 individual BER genes, including uracil-DNA glycosylase (UNG), Single-strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1), Methyl-CpG binding domain 4 (MBD4), thymine DNA glycosylase (TDG), 8-oxoguanine DNA glycosylase (OGG1), MutY DNA glycosylase (MUTYH) and Nei like DNA glycosylase 1 (NEIL1), expression and overall survival (OS) in different clinical data, such as Lauren classification, pathological stages, human epidermal growth factor receptor-2 (HER2) expression status, treatment strategy, gender and differentiation degree in gastric cancer patients, using Kaplan-Meier plotter (KM plotter) online database. [4] LmAbd-9 encodes a glycoprotein with a chitin binding domain 4, belonging to RR-1 subclass of the CPR family, which has two potential O-linked glycosylation sites (S115 and T137) at which glycosylation modification may occur. [5]정제된 단백질을 사용하여 우리는 Ply가 콜레스테롤 결합 도메인 4를 통해 신경 세포막과 상호 작용하여 β-액틴 필라멘트의 외부 표면에 대한 노출을 증가시켜 RrgA 결합에 사용할 수 있는 더 많은 β-액틴 결합 부위를 유도한다는 것을 보여줍니다 , 따라서 뉴런과의 폐렴구균 상호작용이 향상되었습니다. [1] DNA 대사 과정에서 발생하는 주요 불일치인 G:T 불일치는 메틸-CpG 결합 도메인 4(MBD4) 및 티민 DNA 글리코실라제(TDG)와 같은 불일치 특이적 DNA 글리코실라제에 의해 부분적으로 복구됩니다. [2] nan [3] nan [4] nan [5]
Flexible Domain 4
subtilis CdaACD domain and purified full-length GlmM or the GlmMF369 variant lacking the C-terminal flexible domain 4, that the cyclase and phosphoglucomutase form a stable complex in vitro and that GlmM is a potent cyclase inhibitor. [1] subtilis CdaACD catalytic domain and purified full-length GlmM or the GlmMF369 variant lacking the C-terminal flexible domain 4, we show that the cyclase and phosphoglucomutase form a stable complex in vitro and that GlmM is a potent cyclase inhibitor. [2] subtilis CdaACD domain and purified full-length GlmM or the GlmMF369 variant lacking the C-terminal flexible domain 4, that the cyclase and phosphoglucomutase form a stable complex in vitro and that GlmM is a potent cyclase inhibitor. [3]subtilis CdaACD 도메인 및 정제된 전장 GlmM 또는 C-말단 가요성 도메인 4가 없는 GlmMF369 변이체, cyclase 및 phosphoglucomutase가 시험관 내에서 안정한 복합체를 형성하고 GlmM이 강력한 cyclase 억제제임을 확인합니다. [1] subtilis CdaACD 촉매 도메인 및 정제된 전장 GlmM 또는 C-말단 유연한 도메인 4가 결여된 GlmMF369 변이체에서 우리는 cyclase와 phosphoglucomutase가 시험관 내에서 안정적인 복합체를 형성하고 GlmM이 강력한 cyclase 억제제임을 보여줍니다. [2] subtilis CdaACD 도메인 및 정제된 전장 GlmM 또는 C-말단 가요성 도메인 4가 없는 GlmMF369 변이체, cyclase 및 phosphoglucomutase가 시험관 내에서 안정한 복합체를 형성하고 GlmM이 강력한 cyclase 억제제임을 확인합니다. [3]
Recognition Domain 4
However, the fine details of its ligand specificity, and specifically that of carbohydrate-recognition domain 4, the most functionally relevant C-type lectin domain within the receptor, are not completely understood. [1] C-type carbohydrate-recognition domain 4 (CRD4) of the receptor contains the site for Ca2+-dependent interaction with sugars. [2]그러나 리간드 특이성의 세부 사항, 특히 수용체 내에서 가장 기능적으로 관련된 C형 렉틴 도메인인 탄수화물 인식 도메인 4의 세부 사항은 완전히 이해되지 않았습니다. [1] 수용체의 C형 탄수화물 인식 도메인 4(CRD4)는 당과 Ca2+ 의존적 상호작용을 위한 부위를 포함합니다. [2]
Transmembrane Domain 4
Structural modeling indicated that R181 is located at the center of putative transmembrane domain 4 (TM4) and its side chain faces towards TM2 instead of towards the substrate translocation pathway, whereas D198 is located at the border of TM4 and intracellular loop 2 and may electrostatically repulse negatively charged phospholipid head groups. [1] Deletion mutants show that a minimal C-terminal sequence after transmembrane domain 4 (residues 260–275) supports Orai1 internalization. [2]구조 모델링은 R181이 추정되는 막횡단 도메인 4(TM4)의 중심에 위치하고 그 측쇄가 기질 전위 경로 대신 TM2를 향하는 반면 D198은 TM4와 세포내 루프 2의 경계에 위치하고 정전기적으로 반발할 수 있음을 나타냅니다. 음전하를 띤 인지질 헤드 그룹. [1] 삭제 돌연변이는 막횡단 도메인 4(잔기 260-275) 이후의 최소 C-말단 서열이 Orai1 내재화를 지원함을 보여줍니다. [2]
Interaction Domain 4
METHODS The real-time quantitative polymerase chain reaction (RT-qPCR) was used to measure the expression levels of circ_0000517, microRNA-328-3p (miR-328-3p), and AT-rich interaction domain 4B (ARID4B) in HCC tissues and cells. [1] Moreover, ZBED3-AS1 enhanced the expression of AT-rich interaction domain 4B (ARID4B) through sequestering miR-381-3p. [2]행동 양식 실시간 정량적 중합효소연쇄반응(RT-qPCR)을 사용하여 HCC 조직 및 세포. [1] 또한 ZBED3-AS1은 miR-381-3p를 격리함으로써 AT가 풍부한 상호작용 도메인 4B(ARID4B)의 발현을 향상시켰습니다. [2]